<p>安德森霍格兰德公司在最近向证券交易委员会（SEC）提交的 13F 文件中表示，在第三季度将其在 Vertex Pharmaceuticals Incorporated（纳斯达克代码：VRTX - 免费报告）的持仓减少了 19.7%。该公司在此期间出售了 3,880 股后，持有 15,767 股该制药公司的股票。根据其最新的 SEC 文件，安德森霍格兰德公司在 Vertex Pharmaceuticals 的持股价值为 6,175,000 美元。</p>
<p>获取 <strong>Vertex Pharmaceuticals</strong> 警报：</p>
<ul>
<li>皇家制药如何在没有生物技术最大风险的情况下盈利</li>
</ul>
<p>其他几家机构投资者最近也对该公司的持仓进行了调整。美国联合服务汽车协会在第一季度购买了价值约 2,933,000 美元的 Vertex Pharmaceuticals 新股份。李约翰逊资本管理公司在第二季度购买了价值约 721,000 美元的 Vertex Pharmaceuticals 新股份。新泽西州警察和消防员退休系统在第二季度将其在 Vertex Pharmaceuticals 的持股增加了 3.7%。新泽西州警察和消防员退休系统现在拥有 39,035 股该制药公司的股票，价值为 17,378,000 美元，此前在上一季度又增持了 1,393 股。贝拉德公司在第二季度将其在 Vertex Pharmaceuticals 的持股增加了 0.5%。贝拉德公司现在拥有 38,147 股该制药公司的股票，价值为 16,983,000 美元，此前在上一季度又增持了 200 股。最后，SteelPeak Wealth LLC 在第二季度购买了价值约 10,059,000 美元的 Vertex Pharmaceuticals 新股份。对冲基金和其他机构投资者持有该公司 90.96% 的股票。</p>
<h2>Vertex Pharmaceuticals 的内部活动</h2>
<p>在 Vertex Pharmaceuticals 的其他新闻中，执行副总裁查尔斯·F·瓦格纳（Charles F. Wagner, Jr.）在 12 月 3 日（星期三）出售了 14,000 股该股票。该股票以平均价格 456.00 美元出售，总交易额为 6,384,000.00 美元。出售完成后，该执行副总裁直接持有 37,725 股该公司的股票，价值约为 17,202,600 美元。此交易代表其持仓减少了 27.07%。该交易在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。此外，董事长杰弗里·M·莱登（Jeffrey M. Leiden）在 12 月 3 日（星期三）出售了 63,781 股该公司的股票。该股票以平均价格 449.20 美元出售，总价值为 28,650,425.20 美元。出售后，董事长持有 24,026 股该公司的股票，价值为 10,792,479.20 美元。此交易代表其持仓减少了 72.64%。该销售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士已出售 151,073 股公司股票，价值为 67,326,816 美元。公司内部人士持有 0.20% 的股票。</p>
<h2>Vertex Pharmaceuticals 的价格表现</h2>
<ul>
<li>2025 年最佳生物技术股票</li>
</ul>
<p>Vertex Pharmaceuticals 的股票在星期三开盘价为 459.21 美元。该公司的 50 日简单移动平均线为 432.64 美元，200 日简单移动平均线为 425.90 美元。Vertex Pharmaceuticals Incorporated 的 12 个月低点为 362.50 美元，12 个月高点为 519.68 美元。该股票的市值为 1165.1 亿美元，市盈率为 32.38，贝塔值为 0.32。</p>
<p>Vertex Pharmaceuticals（纳斯达克代码：VRTX - 获取免费报告）最近在 11 月 3 日（星期一）发布了季度财报。该制药公司报告季度每股收益（EPS）为 4.80 美元，超出市场共识预期的 4.58 美元，超出幅度为 0.22 美元。Vertex Pharmaceuticals 的净利润率为 31.35%，股本回报率为 23.51%。该公司季度收入为 30.8 亿美元，而市场共识预期为 30.5 亿美元。去年同期，该公司每股收益为 4.38 美元。Vertex Pharmaceuticals 本季度的收入同比增长了 11.0%。分析师预计 Vertex Pharmaceuticals Incorporated 在当前年度将发布 15.63 美元的每股收益。</p>
<h2>分析师评级变动</h2>
<ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
<p>一些股票研究分析师对 VRTX 股票发表了评论。Leerink Partners 将 Vertex Pharmaceuticals 的股票评级从 “市场表现” 上调至 “跑赢大盘”，并在 9 月 25 日的研究报告中将其目标价从 458.00 美元下调至 456.00 美元。瑞银集团在 12 月 4 日的报告中将 Vertex Pharmaceuticals 的评级上调至 “强力买入”。摩根士丹利在 12 月 5 日的研究报告中为 Vertex Pharmaceuticals 设定了 564.00 美元的目标价。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Vertex Pharmaceuticals 的 “持有（c+）” 评级。最后，Evercore ISI 在 9 月 11 日的研究报告中将 Vertex Pharmaceuticals 的目标价从 510.00 美元下调至 475.00 美元，并对该股票设定了 “跑赢大盘” 的评级。三位分析师对该股票给予了强力买入评级，十五位给予了买入评级，九位给予了持有评级。根据 MarketBeat 的数据，Vertex Pharmaceuticals 的共识评级为 “适度买入”，共识目标价为 498.42 美元。</p>
<p><strong>查看我们最新的 VRTX 股票报告</strong></p>
<h2>关于 Vertex Pharmaceuticals</h2>
<p>（免费报告）</p>
<p>Vertex Pharmaceuticals Inc 是一家总部位于波士顿的生物技术公司，专注于严重疾病治疗的发现、开发和商业化。成立于 1989 年，Vertex 以研究驱动的药物开发而闻名，最著名的是其在囊性纤维化（CF）方面的工作，其小分子 CFTR 调节剂的产品组合改变了许多患者的治疗标准。该公司在多个国际市场运营研究与开发、制造和商业组织，为患者和医疗系统提供服务。</p>
<p>Vertex 的上市产品集中在 CFTR 调节剂上，这些药物针对囊性纤维化的根本原因，而不仅仅是治疗症状。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Vertex Pharmaceuticals</li>
<li>可能每月带来$4,290 收益的无聊 AI 投资</li>
<li>警报：在 2026 年 1 月之前抛售这五只股票！</li>
<li>特朗普的 “美国房地产交易” 解读</li>
<li>崩盘前一个月</li>
<li>在 1 月 1 日之前投资$1,000 于这只股票 [不是 NVDA]</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 于 Vertex Pharmaceuticals 吗？</h2>
<p>在考虑 Vertex Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而 Vertex Pharmaceuticals 并不在名单上。</p>
<p>虽然 Vertex Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

福泰制药

<p>安德森霍格兰德公司在第三季度减少了对福泰制药的持股比例，下降了 19.7%，出售了 3,880 股。内部人士出售了 151,073 股，价值 6,730 万美元。福泰的股票开盘价为 459.21 美元，12 个月的价格区间为 362.50 美元至 519.68 美元。分析师的评级各不相同，瑞银将其评级上调至 “强力买入”，摩根士丹利设定了 564 美元的目标价。福泰在第三季度的收益超出预期，收入为 30.8 亿美元，同比增长 11%</p>

<p>Anderson Hoagland &amp; Co. decreased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 19.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,767 shares of the pharmaceutical company's stock after selling 3,880 shares during the period. Anderson Hoagland &amp; Co.'s holdings in Vertex Pharmaceuticals were worth $6,175,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>安德森霍格兰德公司在最近向证券交易委员会（SEC）提交的 13F 文件中表示，在第三季度将其在 Vertex Pharmaceuticals Incorporated（纳斯达克代码：VRTX - 免费报告）的持仓减少了 19.7%。该公司在此期间出售了 3,880 股后，持有 15,767 股该制药公司的股票。根据其最新的 SEC 文件，安德森霍格兰德公司在 Vertex Pharmaceuticals 的持股价值为 6,175,000 美元。</p>
</div><p>Get <strong>Vertex Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Vertex Pharmaceuticals</strong> 警报：</p>
</div><ul>
<li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li>
</ul>
<div class="lb-trans"><ul>
<li>皇家制药如何在没有生物技术最大风险的情况下盈利</li>
</ul>
</div><p>Several other institutional investors have also recently made changes to their positions in the company. United Services Automobile Association purchased a new position in shares of Vertex Pharmaceuticals in the 1st quarter valued at about $2,933,000. Lee Johnson Capital Management LLC purchased a new stake in shares of Vertex Pharmaceuticals during the second quarter worth approximately $721,000. Police &amp; Firemen s Retirement System of New Jersey raised its holdings in Vertex Pharmaceuticals by 3.7% in the second quarter. Police &amp; Firemen s Retirement System of New Jersey now owns 39,035 shares of the pharmaceutical company's stock valued at $17,378,000 after acquiring an additional 1,393 shares in the last quarter. Bailard Inc. raised its holdings in Vertex Pharmaceuticals by 0.5% in the second quarter. Bailard Inc. now owns 38,147 shares of the pharmaceutical company's stock valued at $16,983,000 after acquiring an additional 200 shares in the last quarter. Finally, SteelPeak Wealth LLC purchased a new position in Vertex Pharmaceuticals in the second quarter worth approximately $10,059,000. Hedge funds and other institutional investors own 90.96% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者最近也对该公司的持仓进行了调整。美国联合服务汽车协会在第一季度购买了价值约 2,933,000 美元的 Vertex Pharmaceuticals 新股份。李约翰逊资本管理公司在第二季度购买了价值约 721,000 美元的 Vertex Pharmaceuticals 新股份。新泽西州警察和消防员退休系统在第二季度将其在 Vertex Pharmaceuticals 的持股增加了 3.7%。新泽西州警察和消防员退休系统现在拥有 39,035 股该制药公司的股票，价值为 17,378,000 美元，此前在上一季度又增持了 1,393 股。贝拉德公司在第二季度将其在 Vertex Pharmaceuticals 的持股增加了 0.5%。贝拉德公司现在拥有 38,147 股该制药公司的股票，价值为 16,983,000 美元，此前在上一季度又增持了 200 股。最后，SteelPeak Wealth LLC 在第二季度购买了价值约 10,059,000 美元的 Vertex Pharmaceuticals 新股份。对冲基金和其他机构投资者持有该公司 90.96% 的股票。</p>
</div><h2>Insider Activity at Vertex Pharmaceuticals</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 的内部活动</h2>
</div><p>In other Vertex Pharmaceuticals news, EVP Charles F. Wagner, Jr. sold 14,000 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $456.00, for a total transaction of $6,384,000.00. Following the completion of the sale, the executive vice president directly owned 37,725 shares of the company's stock, valued at approximately $17,202,600. This trade represents a 27.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, Chairman Jeffrey M. Leiden sold 63,781 shares of the company's stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $449.20, for a total value of $28,650,425.20. Following the sale, the chairman owned 24,026 shares of the company's stock, valued at $10,792,479.20. This trade represents a 72.64% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 151,073 shares of company stock valued at $67,326,816. 0.20% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在 Vertex Pharmaceuticals 的其他新闻中，执行副总裁查尔斯·F·瓦格纳（Charles F. Wagner, Jr.）在 12 月 3 日（星期三）出售了 14,000 股该股票。该股票以平均价格 456.00 美元出售，总交易额为 6,384,000.00 美元。出售完成后，该执行副总裁直接持有 37,725 股该公司的股票，价值约为 17,202,600 美元。此交易代表其持仓减少了 27.07%。该交易在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。此外，董事长杰弗里·M·莱登（Jeffrey M. Leiden）在 12 月 3 日（星期三）出售了 63,781 股该公司的股票。该股票以平均价格 449.20 美元出售，总价值为 28,650,425.20 美元。出售后，董事长持有 24,026 股该公司的股票，价值为 10,792,479.20 美元。此交易代表其持仓减少了 72.64%。该销售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士已出售 151,073 股公司股票，价值为 67,326,816 美元。公司内部人士持有 0.20% 的股票。</p>
</div><h2>Vertex Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 的价格表现</h2>
</div><ul>
<li>Best Biotech Stocks to Buy in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年最佳生物技术股票</li>
</ul>
</div><p>Shares of Vertex Pharmaceuticals stock opened at $459.21 on Wednesday. The firm's fifty day simple moving average is $432.64 and its 200-day simple moving average is $425.90. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.68. The stock has a market capitalization of $116.51 billion, a price-to-earnings ratio of 32.38 and a beta of 0.32.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals 的股票在星期三开盘价为 459.21 美元。该公司的 50 日简单移动平均线为 432.64 美元，200 日简单移动平均线为 425.90 美元。Vertex Pharmaceuticals Incorporated 的 12 个月低点为 362.50 美元，12 个月高点为 519.68 美元。该股票的市值为 1165.1 亿美元，市盈率为 32.38，贝塔值为 0.32。</p>
</div><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.58 by $0.22. Vertex Pharmaceuticals had a net margin of 31.35% and a return on equity of 23.51%. The company had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same period last year, the firm posted $4.38 EPS. Vertex Pharmaceuticals's revenue for the quarter was up 11.0% on a year-over-year basis. Analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals（纳斯达克代码：VRTX - 获取免费报告）最近在 11 月 3 日（星期一）发布了季度财报。该制药公司报告季度每股收益（EPS）为 4.80 美元，超出市场共识预期的 4.58 美元，超出幅度为 0.22 美元。Vertex Pharmaceuticals 的净利润率为 31.35%，股本回报率为 23.51%。该公司季度收入为 30.8 亿美元，而市场共识预期为 30.5 亿美元。去年同期，该公司每股收益为 4.38 美元。Vertex Pharmaceuticals 本季度的收入同比增长了 11.0%。分析师预计 Vertex Pharmaceuticals Incorporated 在当前年度将发布 15.63 美元的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
</div><p>A number of equities research analysts have commented on VRTX shares. Leerink Partners raised shares of Vertex Pharmaceuticals from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and dropped their price objective for the company from $458.00 to $456.00 in a research report on Thursday, September 25th. UBS Group raised Vertex Pharmaceuticals to a &#34;strong-buy&#34; rating in a report on Thursday, December 4th. Morgan Stanley set a $564.00 price target on Vertex Pharmaceuticals in a research note on Friday, December 5th. Weiss Ratings reaffirmed a &#34;hold (c+)&#34; rating on shares of Vertex Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Evercore ISI cut their target price on Vertex Pharmaceuticals from $510.00 to $475.00 and set an &#34;outperform&#34; rating on the stock in a research report on Thursday, September 11th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, Vertex Pharmaceuticals has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $498.42.</p>
<div class="lb-trans"><p>一些股票研究分析师对 VRTX 股票发表了评论。Leerink Partners 将 Vertex Pharmaceuticals 的股票评级从 “市场表现” 上调至 “跑赢大盘”，并在 9 月 25 日的研究报告中将其目标价从 458.00 美元下调至 456.00 美元。瑞银集团在 12 月 4 日的报告中将 Vertex Pharmaceuticals 的评级上调至 “强力买入”。摩根士丹利在 12 月 5 日的研究报告中为 Vertex Pharmaceuticals 设定了 564.00 美元的目标价。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Vertex Pharmaceuticals 的 “持有（c+）” 评级。最后，Evercore ISI 在 9 月 11 日的研究报告中将 Vertex Pharmaceuticals 的目标价从 510.00 美元下调至 475.00 美元，并对该股票设定了 “跑赢大盘” 的评级。三位分析师对该股票给予了强力买入评级，十五位给予了买入评级，九位给予了持有评级。根据 MarketBeat 的数据，Vertex Pharmaceuticals 的共识评级为 “适度买入”，共识目标价为 498.42 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on VRTX</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 VRTX 股票报告</strong></p>
</div><h2>About Vertex Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Vertex Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals Inc 是一家总部位于波士顿的生物技术公司，专注于严重疾病治疗的发现、开发和商业化。成立于 1989 年，Vertex 以研究驱动的药物开发而闻名，最著名的是其在囊性纤维化（CF）方面的工作，其小分子 CFTR 调节剂的产品组合改变了许多患者的治疗标准。该公司在多个国际市场运营研究与开发、制造和商业组织，为患者和医疗系统提供服务。</p>
</div><p>Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.</p>
<div class="lb-trans"><p>Vertex 的上市产品集中在 CFTR 调节剂上，这些药物针对囊性纤维化的根本原因，而不仅仅是治疗症状。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Vertex Pharmaceuticals</li>
<li>The boring AI play that could pay up to $4,290 monthly</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>Trump’s “real estate deal for America” explained</li>
<li>A month before the crash</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Vertex Pharmaceuticals</li>
<li>可能每月带来$4,290 收益的无聊 AI 投资</li>
<li>警报：在 2026 年 1 月之前抛售这五只股票！</li>
<li>特朗普的 “美国房地产交易” 解读</li>
<li>崩盘前一个月</li>
<li>在 1 月 1 日之前投资$1,000 于这只股票 [不是 NVDA]</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VRTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 于 Vertex Pharmaceuticals 吗？</h2>
</div><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Vertex Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而 Vertex Pharmaceuticals 并不在名单上。</p>
</div><p>While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Vertex Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Anderson Hoagland & Co. 出售了福泰制药公司 $VRTX 的股票